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M
ultiple and largely redundant mechanisms in the immune system are present to regulate and suppress immune reactivity against selfantigens, thereby protecting the body from autoimmune disease (1) . In one example, Sakaguchi et al. (2) identified a relatively small population of CD4 ϩ T-cells that appear important for control of self-reactive T-cells.
Phenotypic identification indicated these CD4
ϩ T-cells coexpressed the ␣-chain (CD25) of the interleukin (IL)-2 receptor (3). Since that description nearly a decade ago, a plethora of studies have to a large extent supported the notion that CD4 ϩ
CD25
ϩ T-cells, often referred to as CD4 ϩ CD25 ϩ regulatory T-cells (Tregs), play a major role in suppressing immune reactivity (4 -6) . Additional studies in animal models of human disease have indicated that CD4 ϩ CD25 ϩ T-cells, either through decreased frequency or diminished function, may be related to autoimmune disease development (rev. in 7). Indeed, in certain diseasesusceptible strains of mice, transfer of CD4 ϩ CD25 ϩ T-cells prevents the development of autoimmune disease, whereas in other model systems, a variety of pathologies (e.g., gastritis, prostatitis, and thyroiditis) can be produced under situations wherein the development of CD4 ϩ CD25
ϩ T-cells is delayed or outright removed (8 -10) . In one animal model of autoimmune type 1 diabetes, the nonobese diabetic (NOD) mouse, a role for CD4 ϩ CD25
ϩ T-cells in the pathogenesis of disease has been inferred (but not universally supported [11] ) by a variety of methods including but not limited to that of frequency (12) (13) (14) (15) . In humans, a Treg population having the CD4 ϩ CD25 ϩ phenotype has been identified, with the most amenable population being the so-called CD4 ϩ CD25 high T-cells (16 -19) . In terms of functional properties, these Tregs demonstrated an ability to suppress the activities of co-cultured CD4 ϩ CD25 Ϫ responder T-cells as well as being hyporesponsive to non-antigen-specific T-cell stimulation. This population of cells has been intimately related with susceptibility to allergies (20) , whereas for autoimmunity in humans, another study reported decreased frequencies of CD4 ϩ CD25 ϩ T-cells in peripheral blood of patients with systemic lupus erythematosus but not in individuals with rheumatoid arthritis (21) . In terms of type 1 diabetes, one report (22) suggested decreased CD4 ϩ
ϩ T-cell frequencies in human type 1 diabetes, findings similar to a second study investigating subjects with autoimmune polyglandular syndrome type 2 (23) . Given the ever-increasing interest and potential importance of this Treg population as a means for therapeutic intervention (24) , we sought to investigate a potential role for these cells in type 1 diabetes.
RESEARCH DESIGN AND METHODS
We assessed markers of cellular and humoral immunity from 61 children and adults with established type 1 diabetes (25 8 -26) . Hence, a total of 70 type 1 diabetic patients were subject to investigation. All patients with type 1 diabetes were diagnosed according to American Diabetes Association criteria (25) . Healthy control subjects lacked any autoimmune disorders or related probands with type 1 diabetes and were determined to be negative for the presence of either of the type 1 diabetesassociated autoantibodies anti-GAD (GADA) and anti-IA2 (IA2A) (26) . An institutional review board approved informed consents, and assents were obtained for each study participant. Flow cytometry. Heparinized whole blood was collected and immediately subjected to methods for cellular staining. Whole blood (100 l) was aliquoted (per tube) along with each appropriate test antibody, fluorescein ishiocyanate anti-CD3 (clone HIT3a), allophycocyanin (APC) anti-CD4 (SK3), and phycoerythrin (PE) anti-CD25 (M-A251). An extended analysis was conducted on a subset of type 1 diabetic patients and control subjects with PerCP anti-CD4 (SK3), APC-labeled anti-CD62L (DREG-56), CD45RA (HI100), and CD45RO (UCHL1 Fig. 1A ). The regulatory phenotype of the gated CD4 ϩ CD25 ϩ population was confirmed through in vitro suppressive function and expression of the regulatory gene FOXP3 (4) by RT-PCR as previously described (data not shown). Cell culture. Cells were cultured in RPMI 1640 medium (Cellgro, Herndon, VA) supplemented with 5 mmol/l HEPES, 2 mmol/l L-glutamine, penicillin (50 g/ml)/streptomycin (50 g/ml)/neomycin (100 g/ml) (Invitrogen, Carlsbad, CA), 50 mol/l 2-mercaptoethanol, and 5% human type AB serum (Sigma, St. Louis, MO) in U-bottom 96-well plates (Costar, Cambridge, MA). Cell purification. Peripheral blood was collected in sodium-heparinized Vacutainer tubes (BD Biosciences). An accessory cell population (Ͼ98% T-cell depleted) was produced by incubating an aliquot of blood with a T-cell depletion antibody cocktail (StemCell, Vancouver, BC, Canada) followed by density gradient centrifugation according to the manufacturer's instructions (Cellgro). The CD4 ϩ T-cell population was purified by negative selection using a CD4 ϩ T enrichment cocktail (StemCell). After purification and washing in PBS containing 2% serum, the "untouched" CD4 ϩ population then underwent a positive selection for CD4 ϩ CD25 ϩ regulatory T-cells (Ͼ90% pure) using CD25 microbeads (Mitenyi Biotech, Bergisch Gladbach, Germany) with separation on the AutoMACS sorter (Miltenyi). The unlabeled CD4 ϩ CD25 Ϫ population (Ͼ98% pure) provided the CD4 ϩ CD25 Ϫ effector T-cell (Teff) population for use in suppression assays. Suppression assay. A suppression assay was developed to test the capacity of CD4 ϩ CD25 ϩ regulatory T-cells to suppress the proliferation of co-cultured Teffs. Regulatory T-cells were added in decreasing ratios (1:0, 1:1, 1 ⁄2:1, and 0:1) to a constant number of Teffs (5 ϫ 10 3 cells/well). A combination of 5 g/ml soluble anti-CD3 (clone HIT3a) and 2.5 g/ml soluble anti-CD28 (clone CD28.2; eBioscience, San Diego, CA) provided the polyclonal stimulus for proliferation over a 6-day culture period. The 5 ϫ 10 4 irradiated (3,300 rad) T-cell-depleted accessory cells were also added to each well in a total volume of 200 l. Then 1 Ci 3 H-thymidine (Amersham Biosciences, Piscataway, NJ) was added at day 5 for the final 16 h of culture to assess proliferation. Supernatants from six replicate wells were collected for each condition at 24 and 48 h and at day 5 just before the addition of 3 H-thymidine to assess cytokine production. Suppression is determined by the reduction of l was collected from six replicate wells and then diluted 1:2 in tissue culture media before analysis. At the 5-day time point, 20 l was removed from each replicate well and assessed neat. Cytokine concentrations were determined utilizing SOFTmax PRO software (Molecular Devices, Sunnyvale, CA) with four-parameter data analysis. Statistical analysis. Analyses were undertaken using GraphPad Prizm 4.00 software (GraphPad, San Diego, CA), and values at P Ͻ 0.05 were deemed significant. Mann-Whitney U tests were used to compare cellular frequencies, Treg-mediated suppression, and cytokine production results between healthy control subjects and type 1 diabetic subjects. Spearman's correlations were used to compare cellular frequencies with subject age.
RESULTS

CD4
؉
CD25
؉ T-cell frequencies in peripheral blood are stable over short to intermediate periods of time.
To establish the frequency of CD4 ϩ CD25 ϩ T-cells, whole blood was stained with relevant phenotypic markers (CD3, CD4, and CD25) and analyzed by fluorescence-activated cell sorter. Lymphocytes were gated based on scatter and CD3 expression (a representative healthy control is shown in Fig. 1 ) and then analyzed for expression of CD4 and CD25 (Fig. 1B) . To assess the so-called CD4 ϩ CD25 ϩBright T-cells, cells exhibiting a fluorescence intensity of Ͼ100 units were considered positive ( Fig. 1C ), as previously described (21) .
One parameter of interest for studies of CD4 ϩ CD25
ϩ T-cells involved the questions of reproducibility and longitudinal variation within an individual. To assess this aspect, we performed an analysis of CD4 ϩ CD25 ϩ T-cells on 11 healthy control subjects for various amounts of time spanning up to 1 year between the initial test and each subsequent reanalysis. The CD4 ϩ CD25 ϩ T-cell frequency demonstrated a remarkable level of stability ( Fig. 1D ; median coefficient of variation 6.83%, range 1.69 -13.91).
The frequency of CD4
؉ CD25 ؉ T-cells in peripheral blood associates with age. A historical caution for studies of type 1 diabetes, a disorder that often initially presents in children and adolescents, involves a determination of whether age influences the factor under assessment. Therefore, an association analysis was performed on all study subjects correlating age at time of testing versus the CD4 ϩ
CD25
ϩ frequency ( Fig. 2A) , an analysis that revealed increasing age was associated with an increase in total CD4 ϩ CD25 ϩ frequency (r ϭ 0.60, P Ͻ 0.0001). To determine whether this association with age influenced healthy control subjects (Fig. 2B) or type 1 diabetic patients (Fig. 2C) uniquely, similar analyses were performed and indicated that in both study groups, age influenced the frequency of CD4 ϩ CD25 ϩ T-cells (r ϭ 0.64, P Ͻ 0.0001, and r ϭ 0.51, P Ͻ 0.0001, for healthy control subjects and type 1 diabetic subjects, respectively) and that the two groups were not significantly different (NS) in terms of their age associations. In contrast to the age association observed with total CD4 ϩ CD25 ϩ T-cells, no age association with the portion of CD4 ϩ CD25 ϩBright T-cells was identified between healthy control subjects and subjects with type 1 diabetes. This finding suggests that the observed differences as a function of age are likely due to cells expressing low to intermediate levels of CD25. 
ϩ T-cells was plotted, type 1 diabetic patients exhibited lower frequencies than control subjects (Fig. 3A, 15 .21 Ϯ 5.54 vs. 19.03 Ϯ 5.54, respectively; P ϭ 0.0006). This trend was even more pronounced in the new-onset type 1 diabetic group, which averaged only 12.80 Ϯ 2.97 (data not shown, P ϭ 0.0007). However, as indicated previously, a strong association exists between age of a subject at the time of testing and the frequency of CD4 ϩ
ϩ T-cells. Hence, we then performed comparisons between subjects below the age of 20 (a common age limit for studies of age and type 1 diabetes). Interestingly, the frequency of CD4 ϩ CD25 ϩ cells among these two populations, once limits of age were applied, was very similar ( 
FIG. 2. Relationship between CD4
؉ CD25 ؉ T-cell frequency and age at time of testing. Frequency versus age studies in all subjects analyzed (A) (n ‫؍‬ 107; E), normal healthy control subjects (B) (n ‫؍‬ 37; f), and patients with new-onset and established type 1 diabetes (C) (n ‫؍‬ 70; F).
in line with the published "normal" range of ϳ5-10%. Specifically, for healthy control subjects, it is 5.22 Ϯ 2.41%, and for type 1 diabetic patients, it is 4.68 Ϯ 1.84%.
A major focus of attention in immune regulation as it pertains to individuals with type 1 diabetes has been directed at a population of Treg known as CD4 ϩ CD25
ϩBright T-cells. Their definition in terms of gating has not been subjected to universal acceptance, but for our studies, we used a uniform gate across all samples dependent on units of fluorescence intensity. Specifically, we used a definition of those CD4 ϩ CD25 ϩ T-cells with fluorescence intensity of CD25 expression exceeding 100 units as CD4 ϩ CD25 ϩBright T-cells. Under these conditions, no significant difference in frequency was observed between healthy control subjects and the type 1 diabetic population for the percentage of CD4 ϩ CD25 ϩBright T-cells either when all subjects were analyzed (Fig. 3C, 1 .66 Ϯ 1.25 vs. 1.19 Ϯ 0.61, control and type 1 diabetes, respectively) or when these analyses were restricted to subjects under 20 years of age (Fig. 3D, 1 
CD25
ϩ gated T-cell using standardized PE-labeled beads showed slightly higher levels of CD25 per gated cell in the type 1 diabetic population compared with control subjects (949.7 Ϯ 135.9 vs. 834 Ϯ 103.2, P ϭ 0.01).
In an extended analysis of cell markers in a subset of study participants (n ϭ 12 type 1 diabetic patients, n ϭ 8 healthy control subjects), no significant difference was detected in the percentage of cells expressing the markers CD62L (90. 
ϩ T-cells from healthy control subjects (n ϭ 9; mean age 23.75 Ϯ 7.03 years) and patients with type 1 diabetes (n ϭ 10; 18.11 Ϯ 7.77 years) of similar age. These studies indicated that Tregs from patients with type 1 diabetes were functionally deficient in their ability to suppress Teffs in vitro. Specifically, at a ratio of 1 Treg to 1 Teff, type 1 diabetic patients suppressed proliferation less than healthy control subjects (median 14.99, interquartile range Ϫ12.8 to 47.5 and median 63.30, interquartile range 49.36 to 67.05, respectively; P ϭ 0.002) (Fig. 4A, left  plots) . This trend continued in type 1 diabetic patients and healthy control subjects at a ratio of 1 ⁄2 Treg to 1 Teff (right plots, median 7.06, interquartile range Ϫ0.75 to 36.04 and median 46.22, interquartile range 28.47-54.91, respectively; P ϭ 0.008). Under all cell ratios of Treg to Teff (1:0, 1:1, 1 ⁄2:1, and 0:1), the mean cpm in type 1 diabetic patients and healthy control subjects did not differ significantly (Fig.  4B, NS) . Furthermore, Teffs from patients with type 1 diabetes proliferated similarly to healthy control subjects when stimulated by the mitogen phytohemagglutinin (Fig.  4B, 9 .7 ϫ 10 4 Ϯ 2.2 vs. 11.3 ϫ 10 4 Ϯ 3.7 cpm, NS). Interestingly, in certain patients with type 1 diabetes, Tregs not only failed to suppress the proliferation of Teffs, but also acted in synergy, leading to increased proliferation over Teffs alone (Fig. 4A) . Altered cytokine profile from stimulated cultures in patients with type 1 diabetes. To identify mechanistic factors that may contribute to this defect in suppression, supernatants from these suppression assay cultures from type 1 diabetic patients and healthy control subjects were analyzed for the production of a variety of cytokines at periods of 24, 48, and 120 h. Specifically, multiplexed cytokine detection was conducted to measure levels of IL-1␤, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12 (p70), TNF-␣, IFN-␥, and GM-CSF, whereas TGF-␤1 was determined by convention- al enzyme-linked immunosorbent assay. Significant alterations in the levels of IFN-␥ were identified in supernatants from type 1 diabetic patients compared with healthy control subjects at nearly all time points (120 h shown in Fig. 5A ), with diminished production in Teff populations (i.e., 0:1) from type 1 diabetes being the most significant. Patients with type 1 diabetes also displayed a deficiency in the production of TGF-␤1 ( Fig. 5B ; P ϭ 0.03) in Treg cultures (i.e., 1:0). The production of IL-2 and IL-4 in cultures from subjects with type 1 diabetes was also clearly diminished, but in the case of IL-4, such variances were uniform and independent of Treg-to-Teff ratios (Table 1) . At 120 h, a trend toward reduced levels of IL-10 was seen in type 1 diabetic patients (6.9 Ϯ 6.77 vs. 17.1 Ϯ 16.6 pg/ml; Treg:Teff of 1:0), yet the difference was not statistically significant nor were there significant differences at any other time point. Only at the 120-h time point, Teff cultures from healthy control subjects produced higher levels of GM-CSF when compared with type 1 diabetic patients (319.55 Ϯ 190.86 vs. 66.61 Ϯ 35.46 pg/ml, respectively; Treg:Teff 0:1). It is important to note that with one exception (Table 1 ), significant differences in production of the innate mediators IL-1␤, IL-6, and TNF-␣ were not detected at any time point or at any Treg-to-Teff ratio (i.e., differences were not observed with every analyte evaluated). IL-8 levels were at or above the upper limit of detection for the assay (10 ng/ml) in both subject groups, and IL-12 (p70) levels were undetectable at all time points.
FIG. 4. Functional suppression by CD4
؉ CD25 ؉ regulatory Tcells is deficient in patients with type 1 diabetes. Data plotted represent the percent inhibition of proliferation by Tregs from normal healthy control subjects (n ‫؍‬ 9; f) and patients with type 1 diabetes (n ‫؍‬ 10; F). 
DISCUSSION
Despite an abundant interest in CD4
ϩ CD25 ϩ T-cells as they relate to the pathogenesis and perhaps more importantly susceptibility to type 1 diabetes, only limited studies of these cells in humans with the disorder have thus far been reported (22, 23) . To that literature we add our findings that the population of Treg defined by phenotypic expression of the CD4 and CD25 markers does not appear to differ in individuals with type 1 diabetes versus healthy control subjects. In addition, our studies portend that individuals with type 1 diabetes express normal frequencies of CD4 ϩ CD25 ϩBright T-cells. Key to these descriptions regarding "normal" frequencies in most patients with type 1 diabetes was our identification that age-related differences in the percentage of peripheral blood CD4 ϩ CD25 ϩ T-cells exist. However, at a functional level, meaning the ability of Tregs to suppress activities associated with Teff action, key differences were observed between individuals with type 1 diabetes and healthy control subjects. Those differences were associated with deficiencies in production of a number of cytokines. Although these studies support the potential for abnormal immune regulation in type 1 diabetes, it must be emphasized that, to date, there remains no definitive surface marker for Tregs. An additional complicating factor for these types of analyses is the notion that the ␣-chain of the IL-2R (i.e., CD25) is expressed across a continuum of cells, with the most potent suppressor function purportedly attributed to Tregs comprising the bright population using flow cytometric techniques (27) . Such limitations, along with differences in methodology, may explain some of the lack of concordance between our studies with the published studies of Kukreja et al. (22) , which indicated differences in Treg frequency between type 1 diabetic patients and healthy control subjects. In those studies, dramatically lower CD4 ϩ CD25 ϩ T-cells were reported for subjects with type 1 diabetes versus healthy control subjects, with fairly distinct separations of Treg frequencies between the type 1 diabetic and healthy control groups. In our studies reported herein, such differences were not seen, but rather a broad degree of overlap was often observed, suggesting (but not concluding) that heterogeneity may exist within the type 1 diabetic population with respect to any deficiencies associated with these cells. Indeed, some type 1 diabetic patients did present with a remarkably limited number of CD4 ϩ CD25 ϩ T-cells. In addition, we suspect another major difference in findings, and those of Kukreja et al. (22) reside in our inclusion of Supernatants were collected from in vitro suppression assays in subjects with type 1 diabetes or healthy control subjects at 24, 48, and 120 h and at various ratios of regulatory T-to effector T-cells. *P Ͻ 0.01; †P Ͻ 0.05; ND, not detected.
age matching. We note that in the studies of Kukreja et al., the mean age of the new-onset type 1 diabetic population (therein, having the lowest frequency of CD4 ϩ CD25 ϩ T-cells) was 9.4 Ϯ 2.1 years, whereas their healthy control population was 37 Ϯ 5.6 years. As shown in our studies herein, if one does not perform studies on populations of similar age, frequency differences can be observed independent of disease state. These associations with age also mask any effects that disease duration may have on Treg frequencies.
In the end, perhaps the definitive answer on the exact frequency of regulatory populations in cases of autoimmune disorders including type 1 diabetes will only come when populations under scrutiny are matched for age with a definitive marker or set of phenotypic markers identified-a facet that currently does not exist. Yet, even with such an advance, studies of Treg in type 1 diabetes, unlike those of investigating juvenile idiopathic arthritis (28) , would involve extrapolation of results away from the actual site of inflammation (i.e., the pancreatic islets). It is possible that tissue-or lymph node-specific tropisms of Treg could mask important clues as to the pathogenic role of such cells in situations like type 1 diabetes.
The inability to categorically identify a regulatory population of T-cells also points to the heterogeneous nature and natural course of Treg development. A subset of centrally derived regulatory T-cells likely originates from the thymus, whereas others may be generated from the latter stages of effector T-cell differentiation under tolerogenic conditions (3). For our studies, to diminish the possibility that recently activated T-cells expressing CD25 were aberrantly categorized as Treg, we maintained a tight lymphocyte gate across all study populations to reduce the possibility of including large blasting cells but did not exclude cells based on other cellular activation markers. Indeed, a recent article by Fisson et al. (29) showed in a series of in vivo experiments that a subset of Tregs in mice express multiple activation markers. Hence, this type of study would call into question the use of markers of cellular activation to exclude activated nonregulatory cells.
Unfortunately, the mechanisms conferring the suppressive capabilities of Treg are poorly understood, and much of the data that do exist have been derived from murine systems. Most models suggest a requirement for direct cell-to-cell contact between Treg and Teff (7). In terms of soluble factors, direct suppressive functions of Treg appear to act independent of IL-10 and TGF-␤ (30, 31) . Other studies suggest an important role for TGF-␤ based on the association between a reduction of suppression with blockade of TGF-␤ (32, 33) . A role for IFN-␥ in the process has also been suggested by studies involving indoleamine 2,3-dioxygenase and Treg (34, 35) . We would note our desire to have these associations between cytokine elaboration and Treg function confirmed through analysis of larger populations of control subjects and type 1 diabetic patients because our studies were performed on a limited number of subjects.
One potential limitation of these studies is the potential for overinterpretation of a defect lying solely in the CD25 ϩ population over the CD25 Ϫ population because our studies presented herein used CD25 cells from type 1 diabetic patients as responders. Whereas we did not observe significant differences between proliferation of the type 1 diabetic patient and control Teffs, the type 1 diabetic patients' responses as well as IFN-␥ responses were lower. To address the issue of whether the lack of observed suppression did not result from an artifact due to low T effector responses, a series of "crossover" suppression assays were performed in parallel that involved autologous suppression assays and co-incubation of Treg from type 1 diabetic patients with Teff from age-matched control subjects, as well as Treg from control subjects with Teff from type 1 diabetic patients. Preliminary results from those studies (data not shown) do continue to support the notion that the defect resides within the Treg population of patients with type 1 diabetes.
In terms of our providing novel contribution to this literature, our studies would support a clear association between the production of IFN-␥ and TGF-␤ in pathways of suppression by Treg. The production of IL-2, while noted as being reduced in subjects with type 1 diabetes, has for decades been noted as a defect associated with their cellular immune reactivity. In this context, if a dose-dependent influence of IL-2 was required for the maintenance of the suppressive capacity of Treg, differences in the functional assays such as those in this study might be observed. However, with this collective listing of cytokine variances, we must emphasize a notion mentioned previously that direct cell contact between Treg and Teff is thought, by a majority of published studies, to be a key facet to this process. Despite this, it remains plausible to speculate that the production of these cytokines may influence Treg function through effects on antigen-presenting cells and Teff populations.
In terms of future directions and outstanding issues, these studies identified a strong association between age and the frequency of CD4 ϩ
CD25
ϩ T-cells. Yet to be investigated are the interesting questions of whether age influences the regulatory functions of these cells in individuals with type 1 diabetes. Indeed, a study by Tsaknaridis et al. (36) indicates that the suppressive capacity of Treg may actually decline with age. This issue was not addressed as part of the current study because our primary purpose was to determine whether "age matching" was a vital issue for comparisons of frequency in studies of type 1 diabetes. Yet serendipitously, our findings have opened an interesting agenda for future studies that would address the question of whether increases in CD4 ϩ
ϩ T-cells populations with time could, in part, be a physiological response to a decrease in functional capacity or if this increase simply results from a maturation of T-cell populations from increasing antigen exposures. We will also obtain patient samples from both young and old(er) type 1 diabetic patients, matched for age, who have similar disease durations for the purpose of addressing potential issues related to frequency as a function of disease duration. An additional issue not yet addressed here, but will be the subject of future efforts, will examine the potential contributions of various type 1 diabetes susceptibility genes (e.g., HLA, Insulin VNTR, CTLA-4, and SUMO-4) to the observed defects in suppression. Indeed, genetic factors may, like we have seen with age, underlie some of the heterogeneity observed with both function and frequency.
Finally, despite the conflicting reports and substantial overlap in Treg frequencies between type 1 diabetic patients and control subjects, the therapeutic potential of this cell population holds great promise. This study reveals functional defects in a population of cells critical for the maintenance of peripheral tolerance. The future employment of effective treatment modalities using Treg should consider the functional defects outlined herein along with the mechanisms of control underlying them.
